U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H29ClFN5O3.2C4H4O4
Molecular Weight 806.189
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 3
Charge 0

SHOW SMILES / InChI
Structure of HKI-357 DIMALEATE

SMILES

OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CCOC1=CC2=C(C=C1NC(=O)\C=C\CN(C)C)C(NC3=CC(Cl)=C(OCC4=CC(F)=CC=C4)C=C3)=C(C=N2)C#N

InChI

InChIKey=XQJVNEZMRMUPTL-ZMKZOGGKSA-N
InChI=1S/C31H29ClFN5O3.2C4H4O4/c1-4-40-29-16-26-24(15-27(29)37-30(39)9-6-12-38(2)3)31(21(17-34)18-35-26)36-23-10-11-28(25(32)14-23)41-19-20-7-5-8-22(33)13-20;2*5-3(6)1-2-4(7)8/h5-11,13-16,18H,4,12,19H2,1-3H3,(H,35,36)(H,37,39);2*1-2H,(H,5,6)(H,7,8)/b9-6+;2*2-1-

HIDE SMILES / InChI

Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Molecular Formula C31H29ClFN5O3
Molecular Weight 574.045
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Description
Curator's Comment: The description was created based on several sources, including https://clinicaltrials.gov/ct2/show/NCT00550381

HKI-357 is a potent, dual irreversible inhibitor of ErbB2 (HER2) and EGFR. HKI-357 suppresses ligand-induced EGFR autophosphorylation and cell proliferation in NCI-H1975 cells containing L858R and T790M mutations.

Originator

Curator's Comment: # Wyeth, John, and Brother Ltd

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
34.0 nM [IC50]
33.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
2005 Feb 24
Patents

Patents

Sample Use Guides

HKI-357 (7f) was formulated in 0.5% methylcellulose and 2.0% polysorbate-80 (Tween-80) and adminstered orally (80mk/kg, 40 mg/kg or 10 mg/kg) once daily for 20 days
Route of Administration: Oral
Cells were plated in 96-well tissue culture plates (3T3, 3T3/neu, 5000 cells/well; A431, SK-Br-3, BT474, MDA-MB-435, and SW620, 10,000 cells/well). The following day, dilutions of HKI-357 (0.5 ng/ml–5 mkg/ml) were added, and cells were cultured for 2 days (6 days for BT474). Cell proliferation was determined using sulforhodamine B, a protein binding dye.
Substance Class Chemical
Created
by admin
on Sat Dec 16 04:41:41 GMT 2023
Edited
by admin
on Sat Dec 16 04:41:41 GMT 2023
Record UNII
7X764DR931
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
HKI-357 DIMALEATE
Common Name English
(E)-N-(4-(3-CHLORO-4-((3-FLUOROBENZYL)OXY)ANILINO)-3-CYANO-7-ETHOXY-6-QUINOLINYL)-4-(DIMETHYLAMINO)-2-BUTENAMIDE DIMALEATE
Common Name English
Code System Code Type Description
CAS
915942-25-5
Created by admin on Sat Dec 16 04:41:41 GMT 2023 , Edited by admin on Sat Dec 16 04:41:41 GMT 2023
PRIMARY
FDA UNII
7X764DR931
Created by admin on Sat Dec 16 04:41:41 GMT 2023 , Edited by admin on Sat Dec 16 04:41:41 GMT 2023
PRIMARY
PUBCHEM
72941950
Created by admin on Sat Dec 16 04:41:41 GMT 2023 , Edited by admin on Sat Dec 16 04:41:41 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY